Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that they have acquired the full rights to develop and commercialize Kineret (anakinra) from American biotechnology company Amgen for all therapeutic indications. The revised agreement builds on the previous agreement that gave Sobi rights for Kineret within the field of Rheumatoid arthritis (RA) and four orphan drug indications, including Cryopyrin Associated Periodic Syndrome (CAPS).
Help employers find you! Check out all the jobs and post your resume.
